{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:22:13Z","timestamp":1791501733976,"version":"4.3.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,5,31]],"date-time":"2018-05-31T00:00:00Z","timestamp":1527724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"DOI":"10.1093\/jjco\/hyy078","type":"journal-article","created":{"date-parts":[[2018,5,12]],"date-time":"2018-05-12T07:08:59Z","timestamp":1526108939000},"page":"667-672","source":"Crossref","is-referenced-by-count":16,"title":["Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-656X","authenticated-orcid":false,"given":"Hiroki","family":"Ishihara","sequence":"first","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Women\u2019s Medical University Medical Center East, 2-1-10 Nishiogu, Arakawa-ku, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kana","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Women\u2019s Medical University Medical Center East, 2-1-10 Nishiogu, Arakawa-ku, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Tachibana","sequence":"additional","affiliation":[{"name":"Department of Urology, Tokyo Women\u2019s Medical University Medical Center East, 2-1-10 Nishiogu, Arakawa-ku, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Omae","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo"},{"name":"Department of Healthcare Epidemiology, Kyoto University Graduate School of Medicine\/ School of Public Health, Yoshida Konoe-cho, Sakyo-ku, Kyoto"},{"name":"Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, 1 Hikarigaoka, Fukushima City, Fukushima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirohito","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Urology, Kidney Center, Tokyo Women\u2019s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,5,31]]},"reference":[{"key":"key\n\t\t\t\t20180830005349_hyy078C1","first-page":"913","article-title":"EAU guidelines on renal cell carcinoma: 2014 update","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur Urol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C2","first-page":"3584","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C3","first-page":"115","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180830005349_hyy078C4","first-page":"722","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180830005349_hyy078C5","first-page":"1412","article-title":"Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study","volume":"32","author":"Escudier","year":"2014","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C6","first-page":"388","article-title":"A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma","volume":"39","author":"Alasker","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"key\n\t\t\t\t20180830005349_hyy078C7","first-page":"2066","article-title":"Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities","volume":"30","author":"Cohen","year":"2012","journal-title":"Invest New Drugs"},{"key":"key\n\t\t\t\t20180830005349_hyy078C8","first-page":"259","article-title":"Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer","volume":"99","author":"van der Veldt","year":"2008","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180830005349_hyy078C9","first-page":"5","article-title":"Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review","volume":"44","author":"Oh","year":"2014","journal-title":"Int J Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C10","first-page":"1517","article-title":"Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries","volume":"3","author":"Porta","year":"2014","journal-title":"Cancer Med"},{"key":"key\n\t\t\t\t20180830005349_hyy078C11","first-page":"3298","article-title":"Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma","volume":"29","author":"Kawashima","year":"2012","journal-title":"Med Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C12","first-page":"605","article-title":"Sarcopenia and the modified Glasgow prognostic score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line sunitinib treatment","volume":"11","author":"Ishihara","year":"2016","journal-title":"Target Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C13","first-page":"542.e541","article-title":"Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy","volume":"35","author":"Ishihara","year":"2017","journal-title":"Urol Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C14","first-page":"179","article-title":"Systemic therapy in metastatic renal cell carcinoma","volume":"35","author":"Bedke","year":"2017","journal-title":"World J Urol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C15","first-page":"154","article-title":"Evidence and clinical relevance of tumor flare in patients who discontinue tyrosine kinase inhibitors for treatment of metastatic renal cell carcinoma","volume":"68","author":"Iacovelli","year":"2015","journal-title":"Eur Urol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C16","first-page":"2107","article-title":"Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis","volume":"26","author":"Bracarda","year":"2015","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C17","first-page":"1084","article-title":"A 2 weeks on and 1 w eek off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell","volume":"50","author":"Najjar","year":"2014","journal-title":"Eur J Cancer"},{"key":"key\n\t\t\t\t20180830005349_hyy078C18","first-page":"270","article-title":"Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma\u2014comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off","volume":"44","author":"Kondo","year":"2014","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C19","first-page":"791","article-title":"Sunitinib possible sex-divergent therapeutic outcomes","volume":"36","author":"Segarra","year":"2016","journal-title":"Clin Drug Investig"},{"key":"key\n\t\t\t\t20180830005349_hyy078C20","first-page":"411","article-title":"Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: results from the International Metastatic Renal Cell Carcinoma Database Consortium","volume":"122","author":"Kaymakcalan","year":"2016","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20180830005349_hyy078C21","first-page":"576","article-title":"Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients","volume":"45","author":"Akaza","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C22","first-page":"1371","article-title":"Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma","volume":"30","author":"Motzer","year":"2012","journal-title":"J Clin Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C23","first-page":"1166","article-title":"Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma","volume":"40","author":"Tomita","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C24","first-page":"336","article-title":"Safety and activity of sunitinib in elderly patients (>\/= 70 years) with metastatic renal cell carcinoma: a multicenter study","volume":"24","author":"Brunello","year":"2013","journal-title":"Ann Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C25","first-page":"1125","article-title":"Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma","volume":"110","author":"Hutson","year":"2014","journal-title":"Br J Cancer"},{"key":"key\n\t\t\t\t20180830005349_hyy078C26","first-page":"9","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol"},{"key":"key\n\t\t\t\t20180830005349_hyy078C27","first-page":"1175","article-title":"Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma","volume":"47","author":"Ishihara","year":"2017","journal-title":"Jpn J Clin Oncol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/48\/7\/667\/25536222\/hyy078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T19:12:19Z","timestamp":1535656339000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/48\/7\/667\/5025969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,31]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,5,31]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyy078","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7]]},"published":{"date-parts":[[2018,5,31]]}}}